Galectin-3 (LGALS3) and/or galectin-9 (LGALS9) inhibitors are reported in a Galecto Biotech AB patent as potentially useful for the treatment of cancer, autoimmune disease, fibrosis, cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among others.